ANIP

ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ANI Pharmaceuticals recently received final U.S. FDA approval for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension 2mg, 3mg, and 5mg, the generic version of Afinitor Disperz, entering a U.S. market with approximately US$123…

Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026 Post-hoc analyses of baseline characteristics and efficacy outcomes in rescued and non-rescued patients from the Phase 4 NEW DAY trial will be presented in an on-demand ePoster PRINCETON, N.J., Sept.

Investors need to pay close attention to ANIP stock based on the movements in the options market lately.

PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S.

ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie.

ANI Pharmaceuticals currently trades at $76.15 per share and has shown little upside over the past six months, posting a middling return of 3%. The stock also fell short of the S&P 500’s 11.7% gain during that period.

– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company –

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector.